Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Get the latest international news and world events from around the world.

Log in for authorized contributors

Industrial Robot Installations Hit A Record 542,000 Units As Buyers Split Into Two Camps

Global industrial robot installations reached a record 542,000 units in 2024, more than double the figure from a decade earlier, with the International Federation of Robotics valuing those installations at a record $16.7 billion. The headline number hides a sharper split: buyers and investors are separating vendors that are still validating their technology from vendors proving they can deploy it, get paid for it, and repeat the process at scale.

Industrial robot installations just posted their strongest year on record, and the number alone tells only half the story. Global installations reached 542,000 units in 2024, more than double the total from ten years earlier, while the International Federation of Robotics reports the market value of those installations hit a record $16.7 billion, according to GlobeNewswire’s August 2026 coverage. Billions of dollars have poured into AI robotics companies over the past two years, and this is the first year that capital is showing up as hard installation numbers instead of pitch-deck projections.

The scale of the jump matters more than the headline figure alone. Industrial robot installations doubling over a decade tracks a labor shortage that has moved from a manufacturing talking point to a boardroom line item, especially in repetitive, physically demanding roles that companies increasingly can’t staff at any wage. That shortage is the demand-side pressure behind the $16.7 billion figure, and it explains why robotics vendors are no longer competing only on capability, they’re competing on proof that a deployment holds up in production, not just in a demo.

Cancerassociated fibroblast subtypes differentially modulate natural killer cells in cancer

Cancer-associated fibroblasts (CAFs) represent an abundant and heterogeneous component of pancreatic ductal adenocarcinoma (PDAC) but their interplay with natural killer (NK) cells is largely understudied. Rodrigues et al. show that CAFs, particularly myofibroblastic (my)CAF modulate NK anti-tumor capacity. This is mediated partially by prostaglandin E2, affecting granzyme B expression.

AI isn’t close to curing cancer. This startup says it knows what it will take

Very exciting: Vivodyne has built modular robotic laboratories to map vast datasets on biological dynamics at the level of human tissues (not just cells), providing much-needed data for training Bio-AI models to more accurately predict clinical effects.

It’s the data, stupid.

Tunable gene control via RNA splicing with a clinically approved small molecule

et al. developed a DNA sequence module which enables splicing-mediated control of gene expression via an inducer which is already an FDA-approved medicine. An extremely useful advance for gene therapy since it allows activation of therapeutic genes only when we want them to turn on. I expect this kind of tool will be used heavily by the biomedical industry in coming years.

Precise transgene regulation is crucial for the safety and efficacy of next-generation therapies. Here, authors develop RisdiON, a compact gene switch controlled by the approved oral drug risdiplam, showing this system allows for tunable, reversible regulation across diverse applications in vitro and in vivo.

Moderna, Merck vaccine cuts recurrence and spread of melanoma, raising new treatment hope

It is not yet approved, and this does not mean we have “cured cancer.” But it is an extraordinary proof of concept: sequencing + AI/computational biology + mRNA + immunotherapy can be combined to create a treatment tailored to the genetic fingerprint of an individual patient’s tumor.

Moderna and Merck said on Wednesday that a personalized mRNA cancer vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment that sent Moderna’s shares surging as much ‌as 160%.

Scientists turn DNA into a memory device that uses 100x less power

Researchers combined synthetic DNA with a semiconductor to create an ultra-low-power memory device capable of storing and processing information in the same place. The bio-hybrid technology could eventually help make AI systems and next-generation computers far more energy efficient.

A lactateαketoglutarate metabolic circuit in tumorinfiltrating regulatory T cells accelerates tumor progression by inducing NK cell senescence Cancer

Shi et al show that a lactate–α-ketoglutarate metabolic circuit in tumor-infiltrating regulatory T cells promotes WNT2-mediated senescence-like features in natural killer cells and disrupting this axis hinders tumor progression.

Does your immune system learn like AI?

Could AI hold the key to answering questions that have stumped doctors and scientists for decades? A recent study at Cold Spring Harbor Laboratory (CSHL) borrows concepts from machine learning to address an age-old riddle of immunology.

In the thymus, the immune system’s T cells are trained to avoid attacking healthy tissue through a process called negative selection. There, T cells are tested to determine whether they bind to fragments of the body’s own proteins, called self-peptides. Those that do are immediately deleted. However, each T cell encounters only a small fraction of the enormous number of self-peptides found throughout the body. So, how does the immune system learn to tolerate the rest?

“This has long been an open question in immunology,” explains CSHL Assistant Professor Hannah Meyer. “Negative selection is a crucial process, but if T cells had to test against every single one of the body’s peptides, it would take forever. So, how do they learn to avoid friendly fire? We think it’s through a process called generalization.”

/* */